Trial Profile

A phase 4, 15-month, prospective, non-interventional, single-arm, 2-cohort (TD and HD) study of Deutetrabenazine for the treatment of tardive dyskinesia

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 05 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Jun 2024 According to Teva Pharmaceuticals media release, final results from the TD cohort of the Phase 4 START study, which investigated real-world treatment outcomes for patients starting AUSTEDO with the 4-week Titration Kit presented at the 2024 Psych Congress Elevate Annual Meeting, taking place from May 30 - June 2 in Las Vegas, Nevada.
02 Nov 2023 According to Teva Pharmaceuticals media release, interim results from this study will be presented at the Huntington Study Group (HSG) Annual Meeting.
02 Nov 2023 Interim results presented in the Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com